Gilead Sciences (GILD)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$135.82-0.40%
Close 2026-07-08 · 1-day change
Reading GILD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GILD free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading GILD? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track GILD free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Gilead Sciences needs strong product sales growth to justify its current price. Recent earnings showed a revenue increase of 4% year over year and a beat of 6.3%. It trades at 16× P/E, below the peer median of 21×. This suggests the price reflects less growth than expected. A specific risk is the potential for Gilead to cut guidance, which could hurt credibility. Peer multiples imply a price about 4% below where it trades. Our read is provisional.
Trailing returns as of 2026-07-08. GILD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering GILD (as of Jul 2026).
Based on 6 Wall Street analysts offering 12-month price targets for GILD in the last 4 months.
A consensus fair price across 12 valuation methods, at three horizons. Current price $135.82. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Increase product sales excluding Veklury
HSBC upgrade indicates confidence in Gilead's growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-08. EPS is implied from price ÷ P/E. Not investment advice.
Current $135.82
The last 12 months of price, then the range of analyst 12-month targets from today’s $135.82.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Increase product sales excluding Veklury
FDA approval for Trodelvy enhances product sales outlook.
Advances: Increase product sales excluding Veklury
First-line approval could significantly boost oncology sales.
Advances: Increase product sales excluding Veklury
Positive trial results support growth in product sales.
Advances: Increase product sales excluding Veklury
Positive trial results support growth in product sales.
HIV drug approval supports product sales growth.
Advances: Increase product sales excluding Veklury
Regulatory milestone strengthens Gilead's market position.
Faster access to lenacapavir boosts product sales potential.